Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biotechnology Equipment

PUBLISHER: Grand View Research | PRODUCT CODE: 1553571

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1553571

Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (AAV, Lentivirus, Retrovirus), By Application (Gene Therapy, Cell Therapy), By Method (Ex-vivo, In-vivo), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Gene Delivery Technologies Market Growth & Trends:

The global gene delivery technologies market size is expected to reach USD 10.27 billion by 2030, expanding at a CAGR of 11.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Technological advancements in viral vectors, a growing pipeline of advanced therapies, and a rising number of regulatory approvals for advance therapy products are some key driving forces of the market.

Several novel tools are being introduced for genetic alterations that have facilitated the scientific community to delineate the disease intricacies at the genomic level, leading to the emergence of novel gene delivery approaches. Furthermore, ongoing research to develop clinically relevant vectors including viral and non-viral vectors to combat chronic illnesses such as cancer, Alzheimer's, and others through advanced therapies is spurring the market revenue.

An increase in investment and financing in the space to support the research, development, and manufacturing of various modes of gene transfer further accelerates the revenue growth. Currently, around 70% of gene and cell therapy programs are based on viral vectors leading to organic revenue growth for biological delivery technologies. The operating players are investing significantly to scale up their viral vector manufacturing capability and meet the growing demand.

Considering growing opportunities in physio-chemical gene delivery approaches, key players are making focused efforts to boost their business presence. For instance, nanoparticles have proven their efficiency as promising vehicles for clinical usage owing to their tunable morphology, and biological behaviors. Such ongoing developments in the space are anticipated to accelerate revenue growth in this market in the coming years.

Gene Delivery Technologies Market Report Highlights:

  • The wide implementation of biological gene delivery technologies in clinical usage owing to their high efficiency and specificity has resulted in the segment's largest revenue share in 2023
  • Gene therapy development is the key revenue-generating application in the 2023 market owing to constantly expanding pipeline programs of therapies against life-threatening conditions coupled with the recent success of CAR-T therapies
  • The recent pandemic of SARS-CoV-2 has also resulted in substantial global investments in R&D of viral vector-based vaccine to combat the virus, resulting in lucrative growth of this segment
  • The ex vivo method accounted for the major revenue share owing to its advantages such as high transduction efficiency and less immunogenic responses
  • However, both in vivo and ex vivo have shown clinical success in the treatment of chronic conditions, thus both segments are expected to witness lucrative growth in the coming years
  • Given the high number of biotech companies and a favorable regulatory environment in the U.S.; North America dominated the global market in terms of revenue
  • On the other hand, Asia Pacific is projected to grow at the fastest pace during the forecast period
  • Constantly evolving CDMO and viral vector manufacturing landscapes through plant expansions and new sites being built across the Asian countries is spurring the adoption of vectors in this region
  • The key players are engaged in collaboration with therapy developers to support their product development process
Show more
Product Code: GVR-4-68039-291-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Gene Delivery Technology Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Gene Delivery Technology Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Gene Delivery Technology Market: Mode Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Gene Delivery Technology Market: Mode Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Biological
    • 4.3.1. Biological Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Adenovirus
      • 4.3.2.1. Adenovirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Retrovirus
      • 4.3.3.1. Retrovirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. AAV
      • 4.3.4.1. AAV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Lentivirus
      • 4.3.5.1. Lentivirus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Other Viruses
      • 4.3.6.1. Other Viruses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.7. Non-viral
      • 4.3.7.1. Non-viral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Chemical
    • 4.4.1. Chemical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Physical
    • 4.5.1. Physical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Gene Delivery Technology Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Gene Delivery Technology Market: Application Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Gene Therapy
    • 5.3.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cell Therapy
    • 5.4.1. Cell Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Vaccines
    • 5.5.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Research
    • 5.6.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Gene Delivery Technology Market: Method Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Gene Delivery Technology Market: Method Movement Analysis, USD Million, 2023 & 2030
  • 6.3. Ex vivo
    • 6.3.1. Ex vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. In vivo
    • 6.4.1. In vivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. In vitro
    • 6.5.1. In vitro Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Global Gene Delivery Technology Market: Regional Estimates & Trend Analysis

  • 7.1. Global Gene Delivery Technology Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Gene Delivery Technology Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Thermo Fisher Scientific Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. QIAGEN
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Horizon Discovery Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. OriGene Technologies, Inc.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Oxford Biomedica PLC
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. SignaGen Laboratories
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Flash Therapeutics
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Takara Bio Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bio-Rad Laboratories, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. System Biosciences, LLC.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Promega Corporation.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. F. Hoffmann-La Roche Ltd
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. SIRION BIOTECH GmbH
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. Catalent, Inc.
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!